Investigation of the effect of Zufa syrup on clinical symptoms in the with suspected Corona (COVID-19)
Phase 3
- Conditions
- Coronavirus.Coronavirus as the cause of diseases classified elsewhereB97.2
- Registration Number
- IRCT20200404046934N1
- Lead Sponsor
- Deouty of Research & Technology Qom University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 130
Inclusion Criteria
Age between 20-70
Lung tissue involvement due to CT scan
Need for medication prescribes Coronavirus treatment
Patients who are treated at home.
Exclusion Criteria
Heart, lung, liver and kidney disease
Blood pressure above 160 mm Hg
Fever above 39. C
Diabetic patients
Pregnancy and lactation
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical signs Includes oxygen saturation, temperature, blood pressure, respiration rate, heart rate. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Individual profile and follow-up questionnaire.;Oxygen levels. Timepoint: During 10 days of treatment and 5 days after treatment. Method of measurement: Oximeter.
- Secondary Outcome Measures
Name Time Method